Researchers reported on 1-year follow-up among patients at 2 centers, all of whom had psoriasis or psoriatic arthritis, after Brazilian health authorities issued a 2017 mandate that patients being treated with the reference infliximab be switched to CT-P13, and that new starts be given the biosimilar instead of the reference.
As more healthcare systems elect to switch patients from reference infliximab to biosimilar CT-P13 (Inflectra, Remsima), more data on the safety and efficacy of the biosimilar begin to emerge from real-world practice. While many of these data are from the European experience with CT-P13, additional data are beginning to be reported in other territories where the biosimilar has gained authorization and has entered the treatment landscape for inflammatory diseases.
One such example is a study published this month researchers from 2 centers in Brazil, where CT-P13 was authorized in 2016 by local authorities. In the study, published in Anais Brasileiros de Dermatologia, researchers reported on 1-year follow-up among patients at the 2 centers, all of whom had psoriasis or psoriatic arthritis, after Brazilian health authorities issued a 2017 mandate that patients being treated with the reference infliximab be switched to CT-P13, and that new starts be given the biosimilar instead of the reference.
The study included 36 patients who had been treated with the reference drug previously and 4 new starts who began treatment with CT-P13. Among the treatment-naïve patients, 2 had psoriatic arthritis. Among the patients who had been treated with the reference drug, 17 had psoriatic arthritis. Patients who had received the reference in the past had a mean 5 years (range, 1-16) of treatment with infliximab before the switch.
During the 1 year of follow-up, 2 patients reported mild worsening of skin lesions, but there was no significant increase in Psoriasis Area and Severity Index (PASI) score observed.
Two patients had infusion-related reactions (IRRs); one occurred in a treatment-naïve patient during the second infusion of infliximab, and the other occurred in a patient who has previous treatment with the reference, but had stopped treatment 4 months prior dur to a medication shortage. This second patient experienced the IRR during the first infusion of the biosimilar.
One patient developed tuberculosis (TB), after which treatment with infliximab was discontinued and treatment for TB was initiated.
The remaining 35 patients had no IRRs or adverse events and had controlled skin and joint symptoms. Their PASI scores ranged from 0 to 2.7.
“Studies with larger cohorts and longer follow-up are still needed,” write the authors, “but our preliminary results show that biosimilars may provide an opportunity to reduce health system costs because of their similarity to reference drugs in terms of safety and efficacy.”
Reference
Kurizky PS, Galvão LO, Martinis GA. Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up. An Bras Dermatol. 2019;94(4):483-484. doi: 10.1590/abd1806-4841.20198358.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
March 9th 2024The adalimumab biosimilar SB5 was reported to be as safe and effective as the reference product in a review of randomized controlled trials and real-world studies on immune-mediated inflammatory diseases.